Allianz Asset Management GmbH lowered its holdings in Immunomedics, Inc. (NASDAQ:IMMU) by 37.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 123,910 shares of the biopharmaceutical company’s stock after selling 73,128 shares during the period. Allianz Asset Management GmbH owned approximately 0.08% of Immunomedics worth $1,732,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of IMMU. Nicholas Investment Partners LP bought a new stake in shares of Immunomedics during the 3rd quarter worth approximately $4,673,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of Immunomedics by 150.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 468,380 shares of the biopharmaceutical company’s stock worth $6,548,000 after acquiring an additional 281,032 shares during the period. Trexquant Investment LP lifted its holdings in shares of Immunomedics by 175.7% during the 3rd quarter. Trexquant Investment LP now owns 79,923 shares of the biopharmaceutical company’s stock worth $1,117,000 after acquiring an additional 50,939 shares during the period. American International Group Inc. lifted its holdings in shares of Immunomedics by 8.1% during the 3rd quarter. American International Group Inc. now owns 68,533 shares of the biopharmaceutical company’s stock worth $958,000 after acquiring an additional 5,125 shares during the period. Finally, NEXT Financial Group Inc lifted its holdings in shares of Immunomedics by 6.8% during the 3rd quarter. NEXT Financial Group Inc now owns 110,750 shares of the biopharmaceutical company’s stock worth $1,298,000 after acquiring an additional 7,100 shares during the period. 76.28% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently weighed in on IMMU. Jefferies Group upped their price target on shares of Immunomedics from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, September 19th. Zacks Investment Research downgraded shares of Immunomedics from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a report on Friday. Finally, ValuEngine downgraded shares of Immunomedics from a “hold” rating to a “sell” rating in a report on Monday, December 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $15.33.

In related news, insider Behzad Aghazadeh acquired 1,325,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was acquired at an average cost of $10.47 per share, for a total transaction of $13,872,750.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Brian A. Markison sold 8,390 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $11.89, for a total transaction of $99,757.10. Following the transaction, the director now owns 99,178 shares of the company’s stock, valued at $1,179,226.42. The disclosure for this sale can be found here. 6.60% of the stock is owned by corporate insiders.

Shares of Immunomedics, Inc. (NASDAQ:IMMU) opened at $14.65 on Tuesday. Immunomedics, Inc. has a twelve month low of $3.30 and a twelve month high of $14.65. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of -0.29. The firm has a market cap of $2,230.00, a P/E ratio of -6.54 and a beta of 1.51.

COPYRIGHT VIOLATION NOTICE: “Allianz Asset Management GmbH Sells 73,128 Shares of Immunomedics, Inc. (IMMU)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/allianz-asset-management-gmbh-sells-73128-shares-of-immunomedics-inc-immu/1783223.html.

Immunomedics Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.